drug protocol number

CQAW039A2316

drug sponsor

Novartis

drug study

QAW039/Fevipiprant

drug trial site

King Fahad Medical City (Riyadh), King Abdulaziz Medical City NG (Jeddah)

drug status

Ongoing

drug phase